Oxford and AstraZeneca did not immediately respond to Reuters’ request for comment.
The first results of tests for a vaccine against the coronavirus under development by the University of Oxford, in collaboration with AstraZeneca Plc, show that it produces a robust immune response in the elderly, the group most at risk, the Financial Times reported on Monday.
The vaccine has been found to trigger protective antibodies and T cells in older age groups, the journal said, citing two people familiar with the discovery, encouraging researchers as they search for evidence that it will spare people later in life from serious illness or death. virus.
The findings echo data released in July that showed the vaccine generated “robust immune responses” in a group of healthy adults between the ages of 18 and 55, the journal reported, citing people with knowledge of the results of so-called immunogenicity blood tests.
But the FT warned that positive immunogenicity tests do not guarantee that the vaccine will ultimately prove to be safe and effective in older people.
AstraZeneca, which is developing the vaccine with researchers at the University of Oxford, is seen as a pioneer in the race to produce a vaccine to protect against COVID-19.
Details of the discovery are expected to be published soon in a clinical journal, the FT said, without naming a journal.
Oxford and AstraZeneca did not immediately respond to Reuters’ request for comment.
(Except for the title, this story was not edited by GalacticGaming staff and is posted from a syndicated feed.)
